Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.